• The number of incident cases of hepatocellular carcinoma in the countries under study will increase by 29% over the 10-year forecast period, from 6,303 to 8,134.
  • The decline in incidence of hepatocellular carcinoma due to improved control of HBV and HCV infection will be countered by an aging population and the higher risk of hepatocellular carcinoma in these older age-groups.
  • We forecast improvements in stage at diagnosis because of closer surveillance of high-risk populations, resulting in an earlier diagnosis. As a result, the proportions of hepatocellular carcinoma cases diagnosed with early-stage disease will increase over the forecast period.

Table of contents

  • Hepatocellular Carcinoma - Epidemiology - Americas
    • Introduction
      • Key Findings
        • Overview
          • Incidence of Hepatocellular Carcinoma per 100,000 People of All Ages per Year in 2019 and 2029
          • Depiction of the Patient Flow in Hepatocellular Carcinoma in the Americas, 2019
          • Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Hepatocellular Carcinoma over the Next Ten Years
          • Diagnosed Incident Cases of Hepatocellular Carcinoma in the Countries Under Study by Stage
          • Number of Additional Incident Cases of Hepatocellular Carcinoma in the Countries Under Study Incurred over 2019-2029
      • Epidemiology Data
      • Methods
        • Lifetime DALYs Gained
        • Newly Diagnosed Incidence
        • Stage Distribution
        • Recurrent Incidence
        • Diagnosed Prevalence
        • Drug-Treatable Populations
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of Hepatocellular Carcinoma
          • Studies Excluded from the Analysis of Hepatocellular Carcinoma
        • Risk/Protective Factors
          • Risk/Protective Factors for Hepatocellular Carcinoma
        • Bibliography
          • Glossary

      Author(s): Oliver Blandy, M.Sc.

      Oliver Blandy, M.Sc., is a senior epidemiologist at DRG, part of Clarivate. Before joining DRG, Oliver worked as a research assistant for Imperial College London, where he was the lead for several studies within an NIRH-funded research group investigating healthcare-associated infections and antimicrobial resistance. He holds an M.Sc. from the University of Bristol, where he specialized in nutrition, physical activity, and public health. He also holds a B.Sc. in chemistry and a postgraduate certificate in education, both from the University of Bristol.


      Related Reports

      Hepatocellular Carcinoma - Landscape & Forecast - Disease Landscape & Forecast

      Hepatocellular carcinoma is a primary malignancy of the liver that commonly arises from liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx) was the only drug approved for advanced disease un...

      View Details

      Hepatocellular Carcinoma | Disease Landscape and Forecast | G7 | 2020

      Hepatocellular carcinoma is a primary malignancy of the liver that commonly arises from liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx) was the only drug approved for advanced disease un...

      View Details

      Hepatocellular Carcinoma - Geographic Focus: China - Hepatocellular Carcinoma - China In-Depth (China)

      MARKET OUTLOOK The hepatocellular carcinoma (HCC) market in China is poised to experience substantial market growth. Availability of systemic targeted drugs is limited, with...

      View Details

      Hepatocellular Carcinoma - Unmet Need - Detailed, Expanded Analysis - Advanced Hepatocellular Carcinoma (US/EU5)

      Hepatocellular carcinoma, the most common type of primary liver cancer, occurs as a results of chronic liver cirrhosis and has a five-year survival rate of only 18%. First-line advanced hepatocellu...

      View Details